Introduction
NK cells are innate lymphoid cells important for host defense against infectious pathogens and cancer (1) . The NK cell response to a potential target relies on the integration of activating and inhibitory receptor signals induced by interaction with the target cell (2, 3) , memory of prior exposures (4), the cytokine milieu (5) , and education during development (6) . Human NK cells are identified via surface expression of CD56 and lack of CD3, and can be categorized into 2 developmentally related, but functionally distinct, subsets based on relative CD56 expression: CD56 bright and CD56 dim (1, 7, 8) . The CD56 dim subset comprises 80%-95% of peripheral blood NK cells. CD56 dim NK cells represent the final stage of NK cell maturation (stage V), and as a result express maturity-related inhibitory receptors (killer cell immunoglobulinlike receptors [KIRs] ), cytotoxic effector proteins (including perforin and granzyme B) at rest, and high surface levels of CD16 (FcγRIIIa), permitting responses to antibody-opsonized targets. The less mature (stage IV) CD56 bright NK cells are a minor subset in the peripheral blood, but predominate in secondary lymphoid tissues. Indeed, CD56
bright NK cells are estimated to outnumber CD56 dim NK cells overall (9) (10) (11) . CD56 bright NK cells express lower levels of cytotoxic effector proteins at rest, partially express CD16, rely on CD94/NKG2A receptors rather than KIRs for selftolerance, and possess distinct chemokine and homing receptor repertoires compared with the CD56 dim subset. CD56 bright NK cells are potent cytokine producers (IFN-γ, TNF, GM-CSF) following combined cytokine receptor stimulation (7, 12, 13) but, unlike CD56 dim NK cells, display minimal antitumor responsiveness at rest. As a result of these properties, CD56
bright NK cells are traditionally considered ineffective antitumor responders that instead function primarily in immunomodulation.
Studies from a number of laboratories have established the antitumor potential of NK cells, chiefly in the setting of allogeneic hematopoietic cell transplantation (HCT) (14) or adoptive NK cell transfer (15, 16) , inspiring substantial interest in NK cellbased immunotherapy (17, 18) . In addition, reports that donor KIR haplotype can influence allogeneic HCT outcomes provide correlative evidence that NK cells mediate a graft-versusleukemia effect in vivo (19) (20) (21) . However, these studies typically do not investigate which NK cell subset is responsible for mediating antitumor responses, and functional analyses have focused NK cells, lymphocytes of the innate immune system, are important for defense against infectious pathogens and cancer. Classically, the CD56 dim NK cell subset is thought to mediate antitumor responses, whereas the CD56 bright subset is involved in immunomodulation. Here, we challenge this paradigm by demonstrating that brief priming with IL- 15 gered with tumor targets for 6 hours, after which degranulation (CD107a surface expression) and cytokine production (intracellular IFN-γ and TNF expression) were assessed ( Figure 1A ). IL-15 priming robustly enhanced degranulation and cytokine production by CD56 bright NK cells in response to K562 acute myeloid leukemia (AML) target cells ( Figure 1B) . Indeed, while IL-15 priming also modestly enhanced CD56 dim NK cell antitumor responses, these were surpassed by those of IL-15-primed CD56 bright NK cells (Figure 1B) . Similar responses to K562 target cells were observed with flow-sorted, control or IL-15-primed CD56 bright and CD56 dim NK cells ( Figure 1C ), indicating that IL-15 priming of CD56 bright NK cell antitumor responses was not a result of competition for IL-15 or differential effector-to-target (E:T) ratios. IL-15 priming of CD56 bright NK cells could be observed after as little as 1 hour of stimulation (Supplemental Figure 1A ; supplemental material available online with this article; https://doi.org/10.1172/JCI90387DS1), and with IL-15 concentrations as low as 1 ng/ml (Supplemental Figure 1B) . In addition, a large proportion of IL-15-primed CD56
bright NK cells exhibited polyfunctional responses, with simultaneous degranulation and IFN-γ and TNF production in response to K562 target cells (Supplemental Figure 2 , A and B). Enhanced responses of IL-15-primed CD56
bright NK cells were also confirmed against the MHC class I-expressing HL-60 AML cell line (Supplemental Figure 2C) .
Since IL-15 is critical for NK cell homeostasis as well as function, we also established that CD56 bright NK cell responses immediately following purification were equivalent to those after overnight culture in media alone (control NK cells) from the same donor (data not shown). Additionally, after 16 hours there was no difference in NK cell viability between control and primed conditions. However, IL-15 priming selectively enhanced CD56 bright NK cell survival in the setting of cytokine withdrawal (Supplemental Figure 3) . Brief IL-15 priming was not sufficient to induce substantial proliferation of CD56 bright or CD56 dim NK cells (Supplemental Figure 4) bright subset, they still exist within a range of maturity states. NK cell maturity can be delineated by the presence or absence of specific surface markers such as KIR, NKG2A, CD57, CD11b, and CD27 (30, 31) . We hypothesized that IL-15 priming of CD56 dim NK cells produced variable responses because immature NK cells were preferentially being primed. We tested this hypothesis using mass cytometry, which permitted simultaneous analysis of more than 30 parameters on each NK cell (Supplemental Table  1 ). Using viSNE (32), we clustered control or IL- 15-primed NK  cells stimulated with K562 tumor targets into CD56  bright , CD56  dim ,  immature CD56 dim , and mature CD56 dim subsets based on the expression of maturity markers that were unaffected by priming (KIR, NKG2A, CD57) as well as CD56 (Figure 2, A dim NK cells that functions in ligand binding and signal transduction. IL-15Rα binds IL-15 with high (picomolar) affinity. IL-15/IL-15Rα can associate with IL-15Rβ/γ either on the same cell (cis-presentation) or on a different cell (trans-presentation) to initiate signaling, although trans-presentation is thought to be the major IL-15R trigger in vivo (22, 23) . Three primary pathways are activated downstream of the IL-15R: JAK1/3/STAT3/5, PI3K/Akt/ mTOR, and Ras/Raf/MEK/ERK (23, 24) . Through these pathways, IL-15 has been shown to promote the survival and proliferation of CD56 bright and CD56 dim NK cells, and to enhance the cytotoxicity of the CD56 dim subset (25) . Prolonged exposure to IL-2, which also acts through the intermediate-affinity IL-2/15Rβγ, has similarly been shown to increase NK cell cytotoxicity (25) . However, IL-2 also promotes regulatory T cell responses, and may thereby limit antitumor immunity (26, 27) . Thus, while IL-15 supports the survival and proliferation of CD56 bright NK cells (22) , its impact on the antitumor responses of this human NK cell subset has not been well examined.
In a model organism, we and others have previously demonstrated that brief priming of murine NK cells with IL-15 optimizes functional responses to tumor or virus-infected targets, including cytokine production and killing (28, 29 bright NK cells were still significantly enhanced by priming; however, no significant differences were observed among CD56 dim NK cells as a whole ( Figure 2C ). Degranulation and IFN-γ production by immature CD56 dim NK cells were significantly enhanced by IL-15 priming, but this increase was not seen in the mature CD56 dim subset ( Figure 2C ). We also compared the fold increase in primed (relative to control) NK cell subsets positive for CD107a, IFN-γ, or TNF upon K562 stimulation (Figure 2D ). For all 3 functional markers, the fold increase was significantly higher for CD56 bright than CD56 dim NK cells, regardless of maturity status. Thus, IL-15 appears to preferentially prime immature CD56 dim NK cells for enhanced degranulation and IFN-γ pro- + NK cells. n = 9 normal donors, 6 independent experiments. Data were compared using a 1-way repeated-measures ANOVA, with Bonferroni's multiple-comparisons testing of indicated groups. *P < 0.05, **P < 0.01, ***P < 0.001. Figure 3A ). To directly assess the ability of IL-15 to augment cytotoxic function, flow-sorted CD56 bright and CD56 dim NK cells were primed with IL-15 for 12-16 hours, and then assessed for cytotoxicity against K562 leukemia targets. IL-15 priming led to a substantial increase in the cytotoxicity of CD56
bright NK cells at all E:T ratios examined, but had a more modest impact on CD56 dim NK cell killing of K562 leukemia targets ( Figure 3 , B and C). We also assessed expression of alternate mediators of NK cell target killing, such as the death receptor ligands TRAIL and Fas ligand. We observed a marked increase in TRAIL following IL-15 priming of CD56 bright NK cells ( Figure 3A ), but did not detect cell surface Fas ligand (not shown). The induced TRAIL Figure 4B ). In contrast, there was no significant difference in the number of tumor conjugates formed by control versus IL-15-primed CD56 dim NK cells at 5 minutes (28.9% ± 5.7% vs. 31.6% ± 4.6%, P = 0.053), 15 minutes (34.9% ± 8.8% vs. 28.9% ± 5.5%, P = 0.17), or 30 minutes (41.6% ± 9.4% vs. 36.8% ± 9.2%, P = 0.16) from the same donors. Thus, one mechanism underlying the enhanced antitumor response of IL-15-primed CD56 bright NK cells involves more effective target recognition or target-cell synapse formation. Therefore, we next examined expression of adhesion molecules and NK cell receptors involved in tumor target recognition with or without IL-15 priming.
IL-15-primed CD56 bright NK cells express more activating receptors and adhesion molecules than control cells. NK cells integrate adhesion molecule, activating and inhibitory receptor, and costimulatory signals, among others, to define their functional responses to target cells (3). We evaluated the surface expression of numerous such signaling molecules by flow cytometry. Expression of the following proteins (percentage positive or median fluorescent intensity) did not differ between control and IL-15-primed CD56 bright NK cells: CD226 (DNAM-1), CD244 (2B4), NKp80, CD94, NKG2A, NKG2C, and CD137 (41BB) (data not shown). In addition, we confirmed no change in KIR (CD158a, CD158b1/2, CD158d, CD158e1/2, and CD158i) or CD57 expression on CD56 bright NK cells following IL-15 priming. However, we did observe significantly increased expression of NKG2D, NKp30, NKp44, CD69, CD2, and CD11a ( Figure 5A and Supplemental Figure 7 ) on IL-15-primed, compared with control, CD56 bright NK cells, in agreement with prior reports (37, 38) . Because of their role in promoting antitumor responses by NK cells, NKG2D, NKp44, NKp30, CD2, and CD11a were thus evaluated for their contribution to IL-15-primed CD56 bright NK cell responses to tumor targets. We preincubated IL-15-primed NK cells with blocking mAbs against these receptors for 30 minutes, and then triggered the cells with K562 targets. No difference in CD56 bright NK cell degranulation or cytokine production upon NKp44 or NKp30 blockade was observed (data not shown). A small reduction in the priming response was observed when CD11a, CD2, or NKG2D was blocked individually. However, priming was significantly diminished upon simultaneous block- bright NK cells that formed NK/K562 conjugates after 5, 15, and 30 minutes of coincubation. n = 4 normal donors, 2 independent experiments. Data were compared using a paired Student's t test. *P < 0.05, **P < 0.01. (33, 39, 40) . Integrins typically exist in a bent conformation with low ligand-binding affinity. However, signals from activating receptors promote integrin activation via inside-out signaling, leading to high-affinity conformation changes and integrin clustering (41). bright NK cells. Summary data show mean ± SEM percentage pERK hi control or primed CD56 bright NK cells (pERK hi cutoff set on baseline control cells). Data were compared using (A) a paired Student's t test, (B) a 1-way ANOVA with Bonferroni's multiple-comparisons testing of indicated groups, or (C) a 1-way repeated-measures ANOVA with Tukey's multiple-comparisons testing. *P < 0.05, **P < 0.01, ***P < 0.001. Figure 9 ). We collected PBMCs from rel/ref MM patients just before, 24 hours after, or 72 hours after a single injection of ALT-803, and immediately assessed NK cell function in response to ex vivo stimulation with U266 myeloma target cells (patient group A) or the traditional NK-sensitive K562 tumor target (patient group B) ( Figure 7C ). Twenty-four hours after ALT-803 administration, patient CD56 bright NK cell degranulation and cytokine production in response to MM and leukemia target cells were significantly increased compared with pretherapy values ( Figure 7D ). However, this priming effect was relatively transitory in vivo, and responses no longer differed significantly from those observed before therapy by 72 bright NK cells, we next examined signaling mechanisms that could be responsible for priming of the CD56 bright subset by IL-15. In mice, IL-15-induced activation of the PI3K/Akt/mTOR pathway is of particular importance for promoting NK cell cytotoxicity (49, 50) , and mTOR activity downstream of the IL-15R has been shown to increase granzyme B expression in both murine and human NK cells (50) . We confirmed that CD56 bright and CD56 (42) . Consistent with this, we observed a modest but significant increase in activated LFA-1 expression on CD56
bright NK cells as a result of IL-15 priming alone ( Figure 5C ). However, the majority of IL-15-primed CD56 bright NK cells expressed high-affinity LFA-1 after 15 minutes of incubation with K562 target cells, whereas K562 coincubation induced highaffinity LFA-1 on only a small subset of control CD56 bright NK cells ( Figure 5C ). Signaling through LFA-1 has been shown to activate ERK1/2 (43) (outside-in signaling), and enhanced ERK1/2 phosphorylation was observed in IL-15-primed CD56 bright NK cells trigged with K562 targets compared with control cells ( Figure 5C ). Thus, IL-15 priming promotes integrin activation on CD56 bright NK cells, potentially allowing adhesion to target cells in the absence of signals from other activating receptors (39) , and also enhances subsequent target-induced inside-out and outside-in signaling.
IL Figure 6A and Supplemental Table 2 ). IL-15 priming resulted in a significant increase in AML blast killing by CD56 bright , as well as CD56 dim , NK cells ( Figure 6A ). In addition, since IL-15 is currently being tested in clinical trials for cancer therapy (44, 45), we investigated whether IL-15 could prime the endogenous CD56 bright NK cells of patients with AML. Control or IL-15-primed peripheral blood mononuclear cells (PBMCs) from newly diagnosed AML patients were triggered with autologous AML blasts ( Figure  6B ) or K562 leukemia targets (Supplemental Figure 8A) , and NK cell functional responses were assessed. Indeed, we observed significant enhancement of patient CD56 bright NK cell antitumor responses against both target cell types following IL-15 priming, with modest enhancement of CD56 dim NK cell responses. Next, the ability of IL-15-primed CD56 bright NK cells to control leukemia in vivo was investigated by engrafting of groups of NOD-SCID-IL2Rγ -/-(NSG) mice with either equal numbers of luciferase-expressing K562 cells (K562-luc) and ALT-803-primed CD56 bright NK cells, or K562-luc cells alone, via i.v. injection. ALT-803 is an IL-15 superagonist complex exhibiting better pharmacodynamics and pharmacokinetic properties than recombinant IL-15 (46) . ALT-803 is currently in clinical trials for cancer immunotherapy (47, 48) . Both groups of mice received ALT-803 after cell engraftment ( Figure 6C ). We observed significantly lower tumor burden as assessed by whole-body bioluminescence imaging in mice treated with ALT-803-primed CD56 bright NK cells (Figure 6, D and E bright NK mouse at different imaging time points. (E) Summary data of whole-body bioluminescence (photons per second) in the different treatment groups. Data show the mean ± SEM photons per second at each time point. n = 8 mice per group, 2 independent experiments. Data were compared using (A and B) a 1-way repeated-measures ANOVA with Bonferroni's multiple-comparisons testing of indicated groups or (E) a 2-way ANOVA with Sidak's multiple-comparisons testing. *P < 0.05, **P < 0.01, ***P < 0.001. fact of differential inhibitor affinity or E:T ratio, we repeated these experiments with flow-sorted CD56 bright or CD56 dim NK cells pretreated with both Ly294002 and PD98059. The same pattern of response was observed ( Figure 9C and Supplemental Figure 11A) Figure 9B ). To confirm that the functional response abrogation conferred by PI3K or MEK inhibition was not an arti- bright NK cells were transient, persisting for less than 72 hours after stimulation in vitro and in vivo in patients. This is disure 9D), and significantly reduced killing of K562 leukemia target cells ( Figure 9E ). While the effect of PI3K and MEK inhibition on CD56 dim NK cell cytotoxic protein expression was more modest (Supplemental Figure 11B) , K562 killing was significantly reduced as a result of treatment with these inhibitors (Supplemental Figure  11C) . Thus, both the PI3K/Akt/mTOR and Ras/Raf/MEK/ERK pathways appear to be important for IL-15 priming of CD56 bright NK cells, while the PI3K/Akt/mTOR pathway was not required for the functional response of IL-15-primed CD56 dim NK cells. Interestingly, our phosphorylation studies indicated that phosphorylated Akt (pAkt) expression is similar between unstimulated CD56 bright and CD56 dim NK cells but pERK is significantly higher in CD56 dim NK cells at baseline ( Figure 8C ). Thus, it is possible that a certain threshold of MEK/ERK pathway activation is required for significant antitumor responses, which is not achieved in nonprimed CD56 bright NK cells or NK cells treated with PD98059.
Discussion
Numerous functional and phenotypic properties have been used to distinguish CD56 bright from CD56 dim NK cells, including the superior ability of resting CD56 dim NK cells to be triggered by tumor targets or activating receptor ligation, and to mediate cytotoxicity. Here, we identified that brief priming through the con- bright NK cells were incubated with K562 tumor targets (E:T = 2.5:1) in a 4-hour flow-based killing assay. Summary data show mean ± SEM percentage specific killing. n = 12 normal donors, 8 independent experiments. Data were compared using (A and B) a paired Student's t test or (C-E) a 1-way repeated-measures ANOVA with Tukey's multiple-comparisons testing. *P < 0.05, **P < 0.01, ***P < 0.001.
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NK cells. The reasons for this differential responsiveness to IL-15 are unclear and warrant further investigation. Possibilities include SHIP1, which dephosphorylates the PI3K product PIP 3 , and has been shown to have lower expression in CD56 bright than in CD56 dim NK cells, suggesting that this pathway is subject to less inhibition in the CD56 bright subset (66) . However, CD56 bright NK cells have also been shown to express higher levels of PTEN, another inhibitor of the PI3K/Akt pathway (67) . Additional studies linking IL-15R signals to distinct functions are warranted.
This study has translational relevance to several cancer immunotherapy settings, including the adoptive transfer of allogeneic NK cells (17, 68) . Patients who receive allogeneic NK cell infusions are typically prepared with lymphodepleting chemotherapy, which has been shown to induce IL-15 protein in the serum (15, 68) . Thus, in this situation, CD56
bright NK cells that are present in the enriched NK cell product are likely primed in vivo by IL-15. Differences in the NK cell receptor biology of CD56 bright NK cells may also influence their antileukemic function. Since only a small fraction of CD56 bright NK cells express inhibitory KIRs, most inhibitory signals are mediated via CD94/NKG2A (7, 34) . Thus, depending on their activation state, the CD56 bright subset has the potential to respond to leukemia cells regardless of donor/recipient KIR/ KIR-ligand mismatch status. In our experiments, IL-15-primed CD56 bright NK cells effectively responded to primary AML blasts without blocking CD94/NKG2A (or other inhibitory receptors). This suggests that IL-15 priming may alter the threshold of activation for CD56 bright NK cells, resulting in triggering by leukemia targets regardless of inhibitory signals. These findings are in line with reports of in vitro CD137L/IL-15-expanded bulk NK cells, for which activating receptor signals dominated inhibitory KIR signaling (69) . Moreover, IL-15 or IL-15/IL-15Rα complexes are being investigated in early-stage clinical studies to support adoptively transferred NK cells (70, 71) or as single agents (45) . Our findings suggest that the adoptively transferred or endogenous patient CD56 bright NK cells may contribute to the therapeutic efficacy of IL-15 administration. Finally, since ALT-803, unlike recombinant IL-15, accumulates and persists in secondary lymphoid tissues such as lymph nodes and spleen (72) , treatment with this agent may be particularly apt to provide sustained priming signals to this lymph node-resident NK cell subset (9) .
Another scenario in which IL-15 priming of CD56 bright NK cells may be important is early (1-3 months) after allogeneic stem hematopoietic cell transplantation (HCT). Early after an HCT, CD56 bright NK cells are the major lymphocyte subset to recover in the peripheral blood (73) (74) (75) (76) (77) (78) . Functional CD56 bright NK cell antileukemic responses have not been analyzed in depth in this setting (57). In 2 reports, an "activated" phenotype with an intact CD56 bright response to combined cytokine activation was observed (76, 78) , although responses to leukemia or other target cells were not assessed. In a more recent study focused on KIR + CD56 dim NK cells from HCT recipients, IL-15 stimulation led to a significant enhancement of the antileukemia responses of CD56 dim NK cells; however, the effects of IL-15 on CD56 bright NK cell responses to leukemia cells were not reported (77) . Based on our findings, elevated (or exogenous) IL-15 in the early postallogeneic HCT period may prime CD56
bright NK cells, and thereby promote NK cell clearance of residual AML blasts. Late after HCT, donor NK cells reestaband DC-rich parafollicular areas of secondary lymphoid tissues, and may normally be activated by DC-derived IL-15 (9) (10) (11) . Prior reports demonstrated that CD56 bright NK cells from the peripheral blood, tonsils, and spleen were activated by mature DCs to more effectively prevent B cell transformation by EBV virus, compared with CD56 dim NK cells (59) . These data support the concept that CD56 bright NK cells may be primed in humans in vivo by IL-15 on the surface of DCs or monocytes in secondary lymphoid tissue (11) , and potentially in other sites of IL-15 production such as the bone marrow and spleen (60, 61) , thereby enhancing their functional competence against virally infected or malignantly transformed cells. Previous work has also revealed that exposure to IL-12 or prolonged stimulation with combinations of IL-2, IL-12, and/or IL-15 can increase CD56 bright NK cell cytotoxicity (1, 7, 25, 58, 62, 63) . This prior work identified that CD56 bright NK cells may be cultured over days to weeks into lymphokine-activated killer cells that have increased potency against tumor cell lines. Our results are also consistent with a report evaluating CD56 bright NK cell responses to autologous activated CD4 + T cells, which were found to be enhanced by 4-day culture with different cytokines, including IL-15 (64) . Here, we report that brief cytokine priming via specific signaling pathways transforms immunoregulatory CD56 bright NK cells into robust antitumor effectors exhibiting polyfunctional responses to a diverse set of cancer targets, both in vitro and in vivo. The robust increase in TRAIL expression of IL-15-primed CD56 bright NK cells furthermore suggests that these cells may also offer a substantial therapeutic benefit for TRAIL-sensitive tumors. Collectively, these studies highlight the plasticity of the CD56 bright NK cell subset, and indicate that cytokine cues from the NK cell microenvironment can profoundly alter its functional capacity.
The signaling mechanisms leading to IL-15 priming of CD56 bright NK cells involve the PI3K/Akt/mTOR and Ras/Raf/ MEK/ERK pathways. These pathways were robustly induced by IL-15 in the CD56 bright NK cell subset, and their blockade significantly impaired priming. This finding is consistent with studies investigating murine NK cell cytotoxicity (50) , whereas reports concerning human NK cell cytotoxicity have been conflicting (38, 50, 65) , specifically with regard to the role of mTOR. Similar to reports from another group (38), we found that pretreatment of NK cells with the mTOR inhibitor Torin1 at concentrations that selectively inhibit mTORC1/2 (10 nM) prior to priming did not impact effector responses (CD107a, IFN-γ, TNF) of CD56 bright or CD56 dim NK cells against K562 targets, or impair cytotoxic protein upregulation. Priming-induced increases in antitumor effector responses and cytotoxic protein levels were, however, impeded by Torin1 at concentrations of 1 μM, similar to what has been used in other studies (65) . However, micromolar concentrations result in off-target effects, including inhibition of PI3K (51 Proliferation and viability assays. Purified CFSE-labeled or unlabeled NK cells were incubated for 12-16 hours with media alone (control) or media with 5 ng/ml IL-15 (primed). Cytokines were then washed away, and cells were incubated in media alone for 3-5 days. To interrogate proliferation, after both 3 and 5 days, NK cells were harvested and surfacestained for NK cell markers, and CFSE dilution or intracellular Ki67 expression (BD Biosciences) was assessed via flow cytometry. To interrogate viability, after both 3 and 5 days, NK cells were surface-stained for NK cell markers, then stained for activated caspase-3 and caspase-7 (Cell Event Caspase 3/7 Red, Thermo Fisher Scientific) and annexin V (BD) per the manufacturer's instructions. Baseline viability was determined using acridine orange and propidium iodide (Nexcelom).
Mass cytometry. Mass cytometry functional assays were performed as above. Sample staining and data collection were performed as previously described (56) .
Flow-based killing assay. Flow-based killing assays were performed by coincubation of flow-sorted CD56 bright or CD56 dim NK cells with CFSE-labeled K562 cells or PKH67-labeled (Sigma-Aldrich) primary AML blasts for 4-5 hours and assaying of 7-AAD uptake as previously described (28) . Background spontaneous K562 or AML blast death (no effector control wells) was subtracted to yield percentage specific killing, and in all cases this was less than 5% (K562) or 25% (primary AML blasts). E:T ratios of 5:1, 2 (14, 20, 21) . In summary, CD56 bright NK cells, traditionally considered to be minimally tumor-responsive, are effectively primed by short-term IL-15 exposure to enable potent cytotoxicity, degranulation, and cytokine production in response to a broad array of tumor targets and primary hematologic tumor cells both in vivo and in vitro. This study provides a novel rationale for developing clinical immunotherapy approaches that utilize IL-15 to prime CD56 bright NK cells, and suggests that IL-15-based therapeutics may act in vivo to enhance the antitumor capacity of this NK cell subset.
Methods
Reagents. Antihuman mAbs used in this study are listed in Supplemental Table 5 . Endotoxin-free rhIL-15 was used (Miltenyi Biotec). NK cell purification and cell culture. Anonymous human platelet apheresis donor PBMCs were obtained by Ficoll centrifugation. NK cells were purified using RosetteSep (StemCell Technologies; ≥95% CD56 + CD3 -) or by flow cytometric cell sorting (BD FACSAria II; ≥97% purity) (53) . Cells were cultured in complete RPMI-1640 media containing 10% human AB serum (Sigma-Aldrich) for 12-16 hours (unless otherwise stated) with or without 5 ng/ml rhIL-15. ALT-803 in vitro priming of NK cells was performed at 17.5 ng/ml for 12-16 hours. For assays involving IL-15 signaling pathways, NK cells were preincubated with inhibitors of PI3K (Ly294002) or MEK (PD98059; both Cayman Chemical Co.) alone or in combination for 1 hour prior to priming.
Functional assays to assess degranulation and cytokine production. Normal-donor purified or flow-sorted CD56 bright and CD56 dim NK cells were coincubated with K562 or other cell line targets (E:T ratio of 5:1) for 6 hours, with brefeldin A and monensin (BD Biosciences) added for the final 5 hours. Assessment of CD107a, IFN-γ, and TNF by flow cytometry was performed as previously described (53) . In some experiments, NK cells were preincubated for 30 minutes with anti-NKG2D, -CD2, -CD11a/LFA-1, -NKp44, or -NKp30 blocking mAbs (10 μg/ml) before K562 exposure. group A), and 3 were treated with 3-6 μg/kg ALT-803 i.v. (patient group B). One patient from group A was sampled at 2 independent time points. Peripheral blood samples were drawn before ALT-803 and approximately 24 and 72 hours after the first dose of ALT-803, and functional assays were performed on freshly isolated PBMCs. All patients provided informed consent prior to sample collection and/or treatment. NSG mice were maintained under specific pathogen-free conditions and used in accordance with our animal protocol approved by the Washington University Animal Studies Committee.
Note added in proof
While this paper was in press, data from a clinical trial further corroborated our findings by demonstrating that continuous rhIL-15 infusion enhances cytotoxic CD56 bright NK cells in vivo in patients with cancer (83) .
thresholding was applied using the Bernsen algorithm in ImageJ (15-pixel radius, default parameters) and Watershed segmentation.
Tumor cell conjugation assay. Tumor conjugate formation was assessed by coincubation of purified NK cells with CFSE-labeled K562 cells for 5, 15, or 30 minutes. The frequency of CFSE-positive CD56 bright NK events was used to calculate tumor conjugate percentages (81) .
Integrin ( IL-15 signaling pathway phosphorylation assays. Purified NK cells were incubated with 5 ng/ml IL-15 for 2 hours (pAkt and pERK) or 30 minutes (pSTAT5). Next, cells were fixed in 1.7% paraformaldehyde, permeabilized in 100% methanol, then stained overnight for NK cell surface markers and phospho-signaling molecules.
Flow cytometric analysis. Cell staining was performed as previously described (53) , and data were acquired on a Gallios flow cytometer (Beckman Coulter) and analyzed using Kaluza (Beckman Coulter) or FlowJo (Tree Star) software.
Statistics. Statistical comparisons were performed using a paired Student's t test, 1-way ANOVA, 1-way repeated-measures ANOVA, or 2-way ANOVA with post hoc analyses, where appropriate. A P value less than 0.05 was considered significant (*P < 0.05, **P < 0.01, ***P < 0.001).
Study approval. Patients with newly diagnosed AML provided informed consent under the Washington University IRB-approved protocol 2010-11766 for these studies (Supplemental Table 2 ). Five patients with newly diagnosed MM provided informed consent under the Washington University IRB-approved protocol 2011-02270 for these studies (Supplemental Table 3 ). For 1 patient, PBMCs were available only after 1 round of therapy (4 cycles of Revlimid/Velcade/dexamethasone [RVD] followed by melphalan-conditioned autologous stem cell transplantation). For the above patients, PBMCs or tumor cells were viably cryopreserved and thawed for use in assays.
Five patients with relapsed/refractory MM were treated on a phase I study of ALT-803 and provided informed consent for sample collection under IRB-approved protocol 2011-02270 (Supplemental Table 4 ). Two of the 5 patients were treated with 10 μg/kg ALT-803 s.c. (patient
